Abstract: The anti-PD-L1 antibody (22C3) is used as a companion diagnostic for successful checkpoint inhibitor therapy in head and neck squamous cell carcinoma. The positive predictive value of this assay, however, is less than ideal as a high PD-L1 score does not...
Key Takeaways CRC patient survival correlates with the presence or absence of macrophage biomarkers CD68, CD163, and a lack of PD-L1. Lower levels of ‘M1/anti-tumor’ CD68+ or CD68+CD163– cells correlate with increased survival. Higher levels of ‘M2/pro-tumor’ CD163+...
Key Takeaways Image analysis is able to use immune biomarkers to correlate immune cell presence and localization with patient survival in NSCLC. Patient survival correlates with the presence or absence of CD68 and CD163 macrophage markers, but these markers do not...
Background Historically, immunohistochemistry (IHC) assays have been designed for simplicity of manual pathology, however, this is not always ideal to acquire the appropriate data for patient selection and outcomes. Due to various challenges within the current...
In the downloadable original research article sponsored by Pfizer, the digital tissue analysis was performed using the Flagship Biosciences proprietary Image Analysis platform. The article was published in the Journal: Clinical Cancer Research online first on June 3,...
In partnership with Leap Therapeutics (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, Flagship Biosciences published this downloadable original research article. It was first published on Monday, May 10...
Sign up to receive industry and company news, including The Cut Point, Flagship’s quarterly e-newsletter.
NEWS
Roger Pearce is an Image Analysis Services Manager at Flagship Biosciences. Through expertise in Image Analysis and Digital Pathology, Pearce and his team strive to solve problems for both internal and external clients, pushing their skills and technology to their...
Dr. Henderson is Vice President of Computational & Imaging Sciences at Flagship. With a passion for innovative technology and solving problems for clients, Dr. Henderson not only inspires his team but also pushes the boundaries of what’s possible in our industry....
Unlocking the combined value of Offspring’s innovative pre-clinical solutions with Flagship’s clinical trial data-driven assay solutions. Broomfield, CO, USA and Södertälje, Sweden – January 23, 2024 – Flagship Biosciences, a leader in spatial biology and biomarker...
EVENTS
Meet us at the 2nd annual Spatial Biology for Drug Development Summit. We’re excited to be a Program Partner for the Spatial Biology for Drug Development Summit, returning to Boston for a 2nd year, October 22-24. This year, we’ll dive into the latest in spatial omics...
Meet with us in Boston for World CB & CDx.We’re thrilled to be a Spotlight Partner for the 14th World Clinical Biomarkers and Companion Diagnostics Summit. Join us there to exchange insights with biotech and pharma leaders, researchers, and scientists and to discuss...
Meet with us at booth #25. As a Gold Sponsor for the third annual Spatial Biology East Coast Congress in Boston, we hope you’ll join our experts and over 350 other industry leaders to discuss the transforming field of spatial biology. Examine how spatial biology can...